Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2013-09-27Clinical Trial Update: Oral Colchicine in Men With Castrate Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating oral colchicine in men with castration-resistant prostate cancer has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2013-09-24Clinical Trial Update: Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer [Phase 3]
An extension study assessing the long-term safety of denosumab in patients undergoing androgen deprivation therapy for non-metastatic prosta…
-
FDA approval · 2013-09-11FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer [Phase 3]
A Phase 3 trial evaluating lenalidomide in combination with docetaxel and prednisone in castration-resistant prostate cancer completed, with…
-
CLINICAL_TRIALS trial_result · 2013-07-30Clinical Trial Update: A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects [Phase 1]
Phase 1 study comparing enzalutamide capsule vs tablet for relative bioavailability after a single fasted dose in healthy male subjects; the…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate [Phase 2]
A Phase II trial evaluating a radiolabeled monoclonal antibody for progressive metastatic castration-resistant prostate cancer has completed…
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer [Phase 2]
Phase 2 trial evaluating samarium-153-EDTMP with or without PSA/TRICOM vaccine in men with androgen-insensitive (castration-resistant) prost…
-
CLINICAL_TRIALS trial_result · 2013-06-19Clinical Trial Update: Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer [Phase 2]
Phase 2 clinical trial update of perifosine for metastatic, androgen-independent prostate cancer; the study has completed.
-
FDA approval · 2013-06-17FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2013-06-07Clinical Trial Update: A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 study to determine the maximum tolerated dose of ASG-5ME in patients with castration-resistant prostate cancer.
-
CLINICAL_TRIALS trial_result · 2013-05-20Clinical Trial Update: A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase 2 study of single-agent Carlumab in metastatic castration-resistant prostate cancer completed with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-05-20Clinical Trial Update: An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Intetumumab (CNTO 95) in metastatic castration-resistant prostate cancer has completed a…
-
FDA approval · 2013-05-15FDA Approved: XOFIGO — Original Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved XOFIGO (radium-223 dichloride) as the original application for treating metastatic castration-resistant prostate cancer with sy…
-
FDA approval · 2013-04-25FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) filed by Sanofi-Aventis U.S. LLC.
-
CLINICAL_TRIALS trial_result · 2013-04-17Clinical Trial Update: Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 3]
A Phase 3 trial evaluated adding bevacizumab to docetaxel and prednisone in men with hormone-refractory prostate cancer; results were posted…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 drug-drug interaction study evaluating abiraterone acetate plus prednisone with dextromethorphan and theophylline in metastatic ca…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 study evaluating QT/QTc safety and multi-dose pharmacokinetics of abiraterone acetate plus prednisone in patients with metastatic ca…
-
FDA approval · 2013-03-13FDA Approved: JEVTANA — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for JEVTANA (cabazitaxel) submitted by Sanofi-Aventis U.S. LLC, representing a regulatory action…
-
CLINICAL_TRIALS trial_result · 2013-03-12Clinical Trial Update: Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC [Phase 1]
Phase I trial assessing ZD4054 (Zibotentan) in combination with docetaxel for metastatic castration-resistant prostate cancer; the study has…
-
CLINICAL_TRIALS trial_result · 2013-03-08Clinical Trial Update: Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy [Phase 3]
Phase 3 trial of sunitinib plus prednisone in metastatic castration-resistant prostate cancer after docetaxel failure; the study was termina…
-
CLINICAL_TRIALS trial_result · 2013-02-07Clinical Trial Update: RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer [Phase 2]
Phase 2 trial of RAD001 (everolimus) in metastatic, hormone-refractory prostate cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy [Phase 2]
Phase 2 trial of BMS-275291 in hormone-resistant prostate cancer has completed. The study enrolled men with advanced disease, including thos…
-
CLINICAL_TRIALS trial_result · 2012-12-11Clinical Trial Update: A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating the clinical activity of tanespimycin (IPI-504) in hormone-resistant prostate cancer has completed.
-
FDA approval · 2012-12-10FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)
The U.S. FDA approved a supplemental application for ZYTIGA (abiraterone acetate) submitted by Janssen Biotech, Inc. The approval updates th…
-
CLINICAL_TRIALS trial_result · 2012-10-30Clinical Trial Update: Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy [Phase 3]
Phase 3 trial update for MDV3100 (enzalutamide) in castration-resistant prostate cancer previously treated with docetaxel; results posted af…